alzheimers, page-16

Guess we are all forgetting more than we were ever told, so the Alzheimers subject title seems pretty apt...

Here's a reminder for those with short term memories...

Written Agreements with nine hospitals

October 29 2008
The price per course of USD1,125 for Ropren® in Russia that was signalled in the Chairman’s letter in the 2008 Annual Report has been confirmed. Written agreements with nine hospitals in St Petersburg for supply at that price are currently being finalised. A number of important initiatives in relation to Ropren® distribution throughout the remainder of Russia are close to finalisation and details will be revealed when documentation is complete.


Ropren® Sales and Pricing - Sales have commenced

30 September 2008
Initial sales of Ropren® in countries outside Russia have commenced with prices realised at or above a baseline level of $3,000 for a standard three month course. Volume sales in Russia are expected to commence within weeks.




120,000 Courses per year
22nd April 2008
This process, which was very thorough and well planned, has proven extremely valuable.It revealed an ability to tune the plant in a way that increases its production capacity from a planned 20kg of Bioeffective® R per month, to around 40kg per month, without any material additional capital expenditure. This increased production capacity translates into a total of 10,000 courses of Ropren®per month, or 120,000 courses per year.


Maximize Cash Flows – Increase wealth
2nd April 2008
The Directors of Solagran are pleased to announce details of the path forward that the Board has adopted for the marketing of Ropren® in Russia, and at the same time advise the market that Solagran has terminated discussions with the Menarini Group in relation to a potential strategic partnership.

In deciding to adopt this path forward, the Board took a number of factors into consideration. Foremost among these were three clear goals:

 To maximise cash flows over the period to June 30, 2009 so as to ensure the company would be in a position to pay a substantial dividend to shareholders at that time

 To retain within Solagran the highest possible proportion of the revenues generated by Ropren® sales through the distribution channel in Russia

 To minimise the risk of transferring shareholder wealth from Solagran shareholders to a licensee or strategic partner by licensing the rights to Ropren® before all of its many potential applications have been proven and valued.

End of company quotes.


No need for me to point the obvious inconsistencies that these statements raise.
Who ever advised in a previous post on HC that we should give them more time has more patience than me.